Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BriaCell Therapeutics ( (TSE:BCT) ) has shared an update.
On December 29, 2025, BriaPro Therapeutics Corp., a two‑thirds-owned subsidiary of BriaCell Therapeutics, filed its unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three‑month period ended October 31, 2025, with securities regulators in British Columbia and Alberta, covering results prepared under IFRS and not reviewed by an independent auditor. The filing shows BriaPro remains a development-stage entity with minimal cash, total assets of about $181,000, a shareholders’ deficit of roughly $1.39 million, rising current liabilities including amounts due to related parties, and a quarterly comprehensive loss of about $245,000 driven mainly by higher research and development expenses, underlining its dependence on external funding and the continued financial risk profile for shareholders and related stakeholders.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics, through its two‑thirds-owned subsidiary BriaPro Therapeutics Corp., operates in the biotechnology and pharmaceutical sector, focusing on research and development activities that generate primarily intangible assets and limited cash, funded largely via related-party balances and equity-linked instruments such as warrants.
Average Trading Volume: 4,475
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$21.18M
Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.